Cambridge, UK and Milan, Italy – Axxam S.p.A. and Isogenica Ltd. have announced a partnership to bring together functional bioassay capabilities with unique antibody discovery solutions for biotechnology and pharmaceutical clients.
News
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
- 26 September 2024
Together, both companies can offer end-to-end discovery solutions in the space of antibody drug conjugates (ADC) and other functional antibodies. Both companies are united by shared values of integrity, clear communication, and a passion for science.
Isogenica’s core expertise focuses on small-format VHH single-domain antibodies, sometimes known as ‘nanobodies’. Isogenica offers rapid antibody discovery services exploiting the world’s biggest VHH libraries. Projects are custom-tailored and include a broad spectrum of antibody engineering and characterisation services.
Axxam provides a consolidated expertise across a broad range of discovery platforms for the identification of small molecule compounds for different industrial applications. Axxam offers the access to a discovery library of 450.000 compounds composed of specific subsets, including natural compounds, provides key services including assay development, high-throughput screening and hit-to-lead optimization also as fully integrated discovery solutions from assay development to lead candidate through Axxam’s DiscoveryMAXX application.
“We are delighted to enter this collaboration with Axxam” said Bill Eldridge, CEO of Isogenica. “This partnership signifies an important moment for Isogenica to drive innovation and make a lasting impact on global healthcare clients who now have the opportunity to access Axxam’s high quality solutions and functional assays in the early phases of drug discovery with the aim of generating new valuable leads”.
“Axxam is excited to kick-off this strategic partnership with Isogenica. We are confident this collaboration will create new opportunities to accelerate the discovery of innovative therapeutic solutions. Together, we will unlock greater potential for our clients to bring novel treatments to patients,” said Stefan Lohmer, CEO of Axxam.
“Joining forces between Isogenica and Axxam in the form of a strategic partnership unlock new solutions for our customers and unravel new possibilities for both companies. Isogenica benefitting from the biology powerhouse that is Axxam and Axxam benefitting from the innovative VHH platform developed by Isogenica therefore stepping into a new discovery modality” added Ciriaco Maraschiello, COO of Axxam.
About Axxam
Axxam is a leading contract research organization (CRO) providing integrated early discovery services and solutions across the life sciences industries with headquarters located in Bresso (Milan, Italy). Within the drug discovery disciplines, Axxam supports pharma and biotech companies, start-ups, patient foundations as well as academic groups in their journey from target assessment and hit identification to lead generation over all therapeutic areas and target classes. Axxam’s services include assay development, high-throughput screening and hit-to-lead. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information please visit www.axxam.com.
About Isogenica
Isogenica is a biotechnology contract research organisation (CRO) specialised in small-format antibody discovery. In particular, Isogenica focusses on VHH-single-domain antibodies that offer exceptional robustness, flexibility, and scalability across varied therapeutic and diagnostic applications.
Combining the largest and most diverse synthetic VHH libraries available with a proprietary, cell-free CIS display technology allows screening 1000x more antibodies with greater precision, increasing the chance of finding the perfect fit. Isogenica’s customized solutions are designed to maximize the overall success of drug development projects by providing the right solution with significantly reduced timelines, mitigated risks, and enhanced IP protection. This strategic investment ensures that partners achieve not just short-term milestones but long-term commercial success.
For more information, visit www.isogenica.com